Malignant adenomyoepithelioma of the breast with axillary metastasis: a case report in a patient undergoing EGFR-targeted therapy and literature review

Submitted by Anonymous on

Abstract Malignant Adenomyoepithelioma (MAME) is a very rare tumor derived from the mixed proliferation of glandular epithelium and muscular epithelium. It has a wide spectrum of histomorphology, a high risk of local recurrence and distant metastasis, and there are few...

Renal Functional Reserve and Its Association with eGFR Trajectories and Blood Pressure Patterns in Hypertensives with Preserved Renal Function

Submitted by Anonymous on

AbstractIntroduction Renal Functional Reserve (RFR) is a promising marker for detecting early nephron loss and functional renal mass. Aim We evaluated the relationship between RFR and changes in eGFR over time in hypertensive (HT) and normotensive (NT) individuals. Methods In...

ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting

Submitted by Anonymous on

Unique structural features of firmonertinib enhance binding and activity against EGFR mutant proteins including ex20ins mutant proteins in cell lines and NSCLC animal modelsSuperior anti-tumor activity of ARR-002 in ovarian cancer models compared to single-target or bivalent approaches with favorable...

ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting

Submitted by Anonymous on

Unique structural features of firmonertinib enhance binding and activity against EGFR mutant proteins including ex20ins mutant proteins in cell lines and NSCLC animal modelsSuperior anti-tumor activity of ARR-002 in ovarian cancer models compared to single-target or bivalent approaches with favorable...

ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting

Submitted by Anonymous on

Unique structural features of firmonertinib enhance binding and activity against EGFR mutant proteins including ex20ins mutant proteins in cell lines and NSCLC animal models Superior anti-tumor activity of ARR-002 in ovarian cancer models compared to single-target or bivalent approaches with...

ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting

Submitted by Anonymous on

This is a paid press release. Contact the press release distributor directly with any inquiries. ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual...

Black Diamond Therapeutics (BDTX) Advances Silevertinib Trials in EGFR-Related Cancers

Submitted by Anonymous on

Key Takeaways: Black Diamond Therapeutics BDTX is advancing its silevertinib treatment for EGFR mutations in NSCLC and GBM. The company plans to present updated Phase 2 trial results in 2026, focusing on duration of response and progression-free survival. Black Diamond...

Disparities in Kidney Disease and the Race-Neutral eGFR - Research and Action in NYC’s Public Hospital System

Submitted by Anonymous on

PerspectiveEfforts toward Equity Share on Disparities in Kidney Disease and the Race-Neutral eGFR - Research and Action in NYC’s Public Hospital SystemAuthors: Angelica Bocour, M.P.H., Erin Lewis, M.D., Silas Lee, M.S., and Leo G. Eisenstein, M.D. https://orcid.org/0000-0003-4714-6990Author Info & AffiliationsPublished...

Diabetes Duration Is Associated with Declining Kidney Function: eGFR and CKD Burden Across Duration

Submitted by Anonymous on

Open AccessArticle Diabetes Duration Is Associated with Declining Kidney Function: eGFR and CKD Burden Across Duration by Carmen PantisCarmen Pantis SciProfiles Scilit Preprints.org Google Scholar 1,2,†, Cosmin Mihai VesaCosmin Mihai Vesa SciProfiles Scilit Preprints.org Google Scholar 2,3,*, Timea Claudia GhiteaTimea...

C4 Therapeutics Details MOMENTUM Phase 2 Start, Eyes Near-Term Decision on EGFR Program at Barclays Confab

Submitted by Anonymous on

MarketBeat Week in Review – 12/18 - 12/22 C4 Therapeutics NASDAQ: CCCC outlined near-term clinical plans for its targeted protein degradation pipeline during a presentation at Barclays’ 28th Annual Global Healthcare Conference, highlighting progress in multiple myeloma and an upcoming...

Subscribe to Newsfeed